Literature DB >> 19457353

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Richard R Drake1, Krista Y White, Thomas W Fuller, Elena Igwe, Mary Ann Clements, Julius O Nyalwidhe, Robert W Given, Raymond S Lance, O John Semmes.   

Abstract

The prostate gland secretes many proteins in a prostatic fluid that combines with seminal vesicle derived fluids to promote sperm activation and function. Proximal fluids of the prostate that can be collected clinically are seminal plasma and expressed-prostatic secretion (EPS) fluids. EPS represents the fluid being secreted by the prostate following a digital rectal prostate massage, which in turn can be collected in voided urine post-exam. This collection is not disruptive to a standard urological exam, and it can be repeatedly collected from men across all prostatic disease states. A direct EPS fluid can also be collected under anesthesia prior to prostatectomy. While multiple genetic assays for prostate cancer detection are being developed for the shed epithelial cell fraction of EPS urines, the remaining fluid that contains many prostate-derived proteins has been minimally characterized. Approaches to optimization and standardization of EPS collection consistent with current urological exam and surgical practices are described, and initial proteomic and glycomic evaluations of the of EPS fluid are summarized for prostate specific antigen and prostatic acid phosphatase. Continued characterization of the prostate specific protein components of EPS urine combined with optimization of clinical collection procedures should facilitate discovery of new biomarkers for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457353      PMCID: PMC2720443          DOI: 10.1016/j.jprot.2009.01.007

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  67 in total

1.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Authors:  Jack Groskopf; Sheila M J Aubin; Ina Lim Deras; Amy Blase; Sharon Bodrug; Craig Clark; Steven Brentano; Jeannette Mathis; Jimmykim Pham; Troels Meyer; Michelle Cass; Petrea Hodge; Maria Luz Macairan; Leonard S Marks; Harry Rittenhouse
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

2.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

3.  Comparison of expressed prostatic secretions with urine after prostatic massage--a means to diagnose chronic prostatitis/inflammatory chronic pelvic pain syndrome.

Authors:  M Ludwig; I Schroeder-Printzen; G Lüdecke; W Weidner
Journal:  Urology       Date:  2000-02       Impact factor: 2.649

Review 4.  Cell surface glycoconjugates as onco-differentiation markers in hematopoietic cells.

Authors:  M Fukuda
Journal:  Biochim Biophys Acta       Date:  1985

5.  Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.

Authors:  J Pannek; H G Rittenhouse; C L Evans; J A Finlay; D J Bruzek; J L Cox; D W Chan; E N Subong; A W Partin
Journal:  Urology       Date:  1997-11       Impact factor: 2.649

6.  The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

Authors:  Martijn P M Q van Gils; Daphne Hessels; Onno van Hooij; Sander A Jannink; W Pim Peelen; Suzanne L J Hanssen; J Alfred Witjes; Erik B Cornel; Herbert F M Karthaus; Geert A H J Smits; Gerhard A Dijkman; Peter F A Mulders; Jack A Schalken
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

Review 7.  N-Glycans in cancer progression.

Authors:  Ken S Lau; James W Dennis
Journal:  Glycobiology       Date:  2008-08-13       Impact factor: 4.313

8.  Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.

Authors:  Stacy Loeb; Kimberly A Roehl; C Shad Thaxton; William J Catalona
Journal:  Urology       Date:  2008-04-24       Impact factor: 2.649

9.  Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection.

Authors:  J J Chang; K Shinohara; V Bhargava; J C Presti
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

10.  Large-scale and high-confidence proteomic analysis of human seminal plasma.

Authors:  Bartosz Pilch; Matthias Mann
Journal:  Genome Biol       Date:  2006-05-18       Impact factor: 13.583

View more
  36 in total

1.  Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.

Authors:  Claudia Fredolini; Francesco Meani; Alessandra Luchini; Weidong Zhou; Paul Russo; Mark Ross; Alexis Patanarut; Davide Tamburro; Guido Gambara; David Ornstein; Franco Odicino; Monica Ragnoli; Antonella Ravaggi; Francesco Novelli; Devis Collura; Leonardo D'Urso; Giovanni Muto; Claudio Belluco; Sergio Pecorelli; Lance Liotta; Emanuel F Petricoin
Journal:  AAPS J       Date:  2010-06-12       Impact factor: 4.009

Review 2.  [Proteome-based diagnostic and prognostic biomarkers of prostate cancer].

Authors:  J Neuhaus; E Schiffer; J Siwy; F Mannello; L-C Horn; J-U Stolzenburg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

3.  miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.

Authors:  Holly Lewis; Raymond Lance; Dean Troyer; Hind Beydoun; Melissa Hadley; Joseph Orians; Tiffany Benzine; Kenya Madric; O John Semmes; Richard Drake; Aurora Esquela-Kerscher
Journal:  Cell Cycle       Date:  2013-11-07       Impact factor: 4.534

Review 4.  NMR-based metabolomics studies of human prostate cancer tissue.

Authors:  Ana Rita Lima; Joana Pinto; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Metabolomics       Date:  2018-06-18       Impact factor: 4.290

Review 5.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

Review 6.  Seminal plasma as a diagnostic fluid for male reproductive system disorders.

Authors:  Andrei P Drabovich; Punit Saraon; Keith Jarvi; Eleftherios P Diamandis
Journal:  Nat Rev Urol       Date:  2014-04-08       Impact factor: 14.432

Review 7.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

8.  Proteomic analysis of different period excretory secretory products from Clonorchis sinensis adult worms: molecular characterization, immunolocalization, and serological reactivity of two excretory secretory antigens-methionine aminopeptidase 2 and acid phosphatase.

Authors:  Minghui Zheng; Kunhua Hu; Wei Liu; Hongyu Li; Jingfang Chen; Xinbing Yu
Journal:  Parasitol Res       Date:  2012-12-30       Impact factor: 2.289

9.  In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

Authors:  Simona Principe; E Ellen Jones; Yunee Kim; Ankit Sinha; Julius O Nyalwidhe; Jasmin Brooks; O John Semmes; Dean A Troyer; Raymond S Lance; Thomas Kislinger; Richard R Drake
Journal:  Proteomics       Date:  2013-04-23       Impact factor: 3.984

10.  Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.

Authors:  Julius O Nyalwidhe; Lucy R Betesh; Thomas W Powers; E Ellen Jones; Krista Y White; Tanya C Burch; Jasmin Brooks; Megan T Watson; Raymond S Lance; Dean A Troyer; O John Semmes; Anand Mehta; Richard R Drake
Journal:  Proteomics Clin Appl       Date:  2013-09-13       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.